|
**Overview**: Immune Deficiency 2 Panel**Introduction**: The Immune Deficiency 2 Panel is a diagnostic tool designed to monitor immune status using whole blood samples. In India, primary immunodeficiency disorders (PID) affect ~1 in 10,000â€"50,000 children, while secondary immunodeficiencies (HIV, malnutrition, chemotherapy) are far more common, leading to recurrent infections, poor growth, and high mortality in rural/low-SES populations. High morbidity from under-testing due to limited flow cytometry labs, delayed immunoglobulin replacement or HSCT leading to fatal infections. Per immunology practices aligned with ICMR and Indian Society for Primary Immune Deficiency guidelines, the test employs flow cytometry for comprehensive lymphocyte subsets (CD3, CD4, CD8, CD19, CD20, NK cells, ratios, total lymphocytes) over 1-2 days with high accuracy, valuable for diagnosing combined B/T cell defects, SCID-like conditions, or monitoring HIV. This diagnostic falls under immune profiling and targets children/adults with recurrent/persistent infections, failure to thrive, or family PID history, addressing accurate detection to guide IVIG, antibiotics prophylaxis, or genetic testing. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise immune reconstitution assessment and reducing infection-related mortality. Its whole blood-based approach ensures reliable lymphocyte enumeration.**Other Names**: Imm Def 2 Pnl.**FDA Status**: FDA approved, CLIA certified for hematology/immunology, compliant with 2025 standards.**Historical Milestone**: Extended lymphocyte subset panel standard; in India, used in PID/HIV centers.**Purpose**: The test assesses 8 parameters including CD3 count to guide immune deficiency monitoring, evaluate lymphocyte subsets, inform therapy.**Test Parameters**: 1. CD3 Count, 2. CD4 Count, 3. CD8 Count, 4. CD4/CD8 Ratio, 5. CD19 Count, 6. CD20 Count, 7. Total Lymphocytes, 8. NK Cells.**Pretest Condition**: No fasting required; patients should report recurrent infections or growth failure.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for flow).**Medical History**: Patients should provide details on infection frequency, family history, HIV status.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed immunodeficiency including fatal infections, benefits of profiling, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low lymphocyte count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal subsets indicate immunodeficiency, necessitating specialist input.**Specialist Consultation**: Immunologists should be consulted for management.**Additional Supporting Tests**: Ig levels, genetic testing for confirmation.**Test Limitations**: Requires viable cells; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, PID Studies India 2023. |
